Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
6.12
-0.06 (-0.97%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :22,113
Date :02-25-2017
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

February 7th, 2017|

JERUSALEM, Feb. 7, 2017  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming […]

Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

November 29th, 2016|

Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017

JERUSALEM, Nov. 29, 2016  /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully […]

Oramed Receives Additional $4 Million Milestone Payment From HTIT

October 6th, 2016|

Totaling $29.5 Million in payments from HTIT received to date

JERUSALEM, October 6, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, today announced it has received an additional milestone […]

Oramed to Present at the Aegis Capital Growth Conference

September 19th, 2016|

JERUSALEM, September 19, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth […]